USP Institut Universitari Dexeus
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
2012 · Rafael Rosell, Enric Carcereny, et al. · The Lancet Oncology
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
2009 · Rafael Rosell, Teresa Morán, et al. · New England Journal of Medicine
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
2012 · Zhenfeng Zhang, Jae Cheol Lee, et al. · Nature Genetics